Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

The New England journal of medicine·2026

Same author

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026

Same author

Non-invasive brain stimulation as an experimental treatment approach for bulimia nervosa and binge eating disorders: A meta-analysis and systematic review of literature.

Indian journal of psychiatry·2026

Same author

Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

Blood neoplasia·2026

Same author

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Transplantation and cellular therapy·2026

Same author

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Transplantation and cellular therapy·2026

Search research articles

Related Experiment Video

Updated: Jun 23, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.

Meera Mohan¹, Oliver Van Oekelen², Othman Salim Akhtar¹

¹Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting

|June 14, 2024

Summary

Chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies offer effective treatment for relapsed/refractory multiple myeloma (MM). Optimal selection and sequencing of these immunotherapies are crucial for maximizing patient outcomes.

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Jun 23, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

Oncology
Immunotherapy
Hematology

Background:

Multiple approved chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies show significant efficacy in relapsed/refractory multiple myeloma (MM).
These advanced immunotherapies share overlapping indications, necessitating strategic treatment selection and sequencing.

Purpose of the Study:

To explore optimal selection and sequencing strategies for CAR T-cell and bsAb therapies in relapsed/refractory multiple myeloma (MM).
To identify key factors influencing treatment decisions between CAR T-cell and bsAb options for patients with MM.

Main Methods:

Review of current clinical evidence and treatment guidelines for CAR T-cell and bsAb therapies in MM.
Analysis of patient-specific and disease-specific factors impacting treatment choice and sequencing.

Main Results:

Both CAR T-cell and bsAb therapies demonstrate clinical efficacy in MM.
Sequential administration of CAR T-cell and bsAb therapies has shown positive outcomes.
Treatment selection is influenced by logistical challenges, disease tempo, patient frailty, and toxicity profiles.

Conclusions:

Careful consideration of patient and disease factors is essential for selecting and sequencing CAR T-cell and bsAb therapies in MM.
Strategic sequencing can overcome treatment resistance and improve long-term patient outcomes in relapsed/refractory MM.